ImmunoPrecise Antibodies (IPA) Stock Price, News & Analysis

Company Overview

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Key Stats

• Today's Range: C$6.19 to C$6.70
• 50-Day Range: C$6.50 to C$6.50
• 52-Week Range: C$4.52 to C$8.81
• Volume: 19,980 shs
• Average Volume: 19,376 shs
• Market Capitalization: C$162.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IPA Stock Analysis - Frequently Asked Questions

How have IPA shares performed this year?

ImmunoPrecise Antibodies' stock was trading at C$6.50 at the beginning of 2025. Since then, IPA shares have increased by 0.0% and is now trading at C$6.50.
View the best growth stocks for 2025 here.

How do I buy shares of ImmunoPrecise Antibodies?

Shares of IPA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of ImmunoPrecise Antibodies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoPrecise Antibodies investors own include Kraken Robotics (PNG), Facedrive (FDVRF), TrueContext (PFM), UGE International (UGE), Xebec Adsorption Inc. (XBC.V) (XBC.V), Automatic Data Processing (ADP) and Atlas Engineered Products (AEP).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: CVE:IPA
• CIK: N/A
• Web: immunoprecise.com
• Phone: +1-604-8060626
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 1.70
• Current Ratio: 5.06
• Quick Ratio: 4.29

Sales & Book Value

• Annual Sales: C$19.47 million
• Price / Sales: 8.33
• Cash Flow: C$0.77 per share
• Price / Cash Flow: 8.39
• Book Value: C$2.67 per share
• Price / Book: 2.44

Miscellaneous

• Outstanding Shares: 24,935,000
• Free Float: N/A
• Market Cap: C$162.08 million
• Optionable: Not Optionable
• Beta: N/A